Literature DB >> 2208176

Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder.

A F Olumi1, Y C Tsai, P W Nichols, D G Skinner, D R Cain, L I Bender, P A Jones.   

Abstract

Forty-three transitional cell carcinomas of the bladder of differing grades and stages were examined for reduction to homozygosity for chromosomes 9q, 11p, and 17p. Allelic loss of chromosome 9q was seen in 24 of 38 informative grades II, III, and IV tumors providing further evidence for a bladder tumor suppressor gene on this chromosome. In contrast to the grade-independent involvement of chromosome 9q, allelic losses of chromosomes 11p and 17p were seen only in grade III and IV tumors. The results with chromosome 17p were particularly striking and showed that 0 of 10 grade II versus 20 of 31 grade III and IV tumors had allelic losses for this chromosome harboring the p53 tumor suppressor gene often mutated in other human cancers. The data suggest that cumulative genetic damage is sustained in transitional cell carcinomas and that one of the underlying molecular mechanisms distinguishing low grade from high grade tumors involves chromosome 17p.

Entities:  

Mesh:

Year:  1990        PMID: 2208176

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  The value of the preoperative FISH test in unscreened bladder cancer patients with TUR indications.

Authors:  S V Petrov; K A Malkhasyan; M Yu Ulyanin; E F Abdrakhmanov; R Sh Khasanov
Journal:  Pathol Oncol Res       Date:  2012-06-23       Impact factor: 3.201

Review 2.  Landmarks in non-muscle-invasive bladder cancer.

Authors:  Laura S Mertens; Yann Neuzillet; Simon Horenblas; Bas W G van Rhijn
Journal:  Nat Rev Urol       Date:  2014-07-01       Impact factor: 14.432

3.  Cloning and characterization of the porcine DBC1 gene encoding deleted in bladder cancer.

Authors:  Knud Larsen; Jamal Momeni; Leila Farajzadeh; Christian Bendixen
Journal:  Mol Biol Rep       Date:  2014-09-26       Impact factor: 2.316

4.  Expression of p53 product in Chinese human bladder carcinoma.

Authors:  D W Ye; J F Zheng; S X Qian; Y J Ma
Journal:  Urol Res       Date:  1993-05

5.  Biomarkers in bladder cancer: present status and perspectives.

Authors:  Wun-Jae Kim; Soongang Park; Yong-June Kim
Journal:  Biomark Insights       Date:  2007-03-27

6.  The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma.

Authors:  R J van Moorselaar; T Ichikawa; H E Schaafsma; P H Jap; J T Isaacs; P van Stratum; F C Ramaekers; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1993

7.  Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.

Authors:  G Sauter; G Deng; H Moch; R Kerschmann; K Matsumura; S De Vries; T George; J Fuentes; P Carroll; M J Mihatsch
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

8.  Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer.

Authors:  H Matsumoto; H Matsuyama; K Fukunaga; S Yoshihiro; T Wada; K Naito
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

9.  Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5.

Authors:  J-L Hsieh; C-L Wu; M-D Lai; C-H Lee; C-S Tsai; A-L Shiau
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

10.  Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies.

Authors:  Isil Z Yildiz; Rosemary Recavarren; Henry B Armah; Sheldon Bastacky; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2009-10-14       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.